CN115991787A - 二聚体及其用途 - Google Patents

二聚体及其用途 Download PDF

Info

Publication number
CN115991787A
CN115991787A CN202211470101.6A CN202211470101A CN115991787A CN 115991787 A CN115991787 A CN 115991787A CN 202211470101 A CN202211470101 A CN 202211470101A CN 115991787 A CN115991787 A CN 115991787A
Authority
CN
China
Prior art keywords
isvd
amino acid
ctla4
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211470101.6A
Other languages
English (en)
Chinese (zh)
Inventor
徐霆
郭康平
杨东
王媲琳
金宇灏
汪皛皛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Alphamab Co Ltd
Original Assignee
Suzhou Alphamab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Alphamab Co Ltd filed Critical Suzhou Alphamab Co Ltd
Publication of CN115991787A publication Critical patent/CN115991787A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202211470101.6A 2018-06-05 2019-06-04 二聚体及其用途 Pending CN115991787A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/090012 2018-06-05
CN2018090012 2018-06-05
CN2019086821 2019-05-14
CNPCT/CN2019/086821 2019-05-14
PCT/CN2019/089980 WO2019233413A1 (en) 2018-06-05 2019-06-04 Dimer and use thereof
CN201980037301.2A CN112399973B (zh) 2018-06-05 2019-06-04 二聚体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980037301.2A Division CN112399973B (zh) 2018-06-05 2019-06-04 二聚体及其用途

Publications (1)

Publication Number Publication Date
CN115991787A true CN115991787A (zh) 2023-04-21

Family

ID=68769178

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211470101.6A Pending CN115991787A (zh) 2018-06-05 2019-06-04 二聚体及其用途
CN201980037301.2A Active CN112399973B (zh) 2018-06-05 2019-06-04 二聚体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980037301.2A Active CN112399973B (zh) 2018-06-05 2019-06-04 二聚体及其用途

Country Status (6)

Country Link
US (2) US12281163B2 (https=)
EP (1) EP3802613A4 (https=)
JP (1) JP7359785B2 (https=)
CN (2) CN115991787A (https=)
TW (1) TWI831789B (https=)
WO (1) WO2019233413A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377497B2 (en) * 2017-01-23 2022-07-05 Suzhou Alphamab Co., Ltd. PD-L1 binding polypeptide or composite
CN115991787A (zh) 2018-06-05 2023-04-21 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
JP7712925B2 (ja) * 2019-12-04 2025-07-24 江蘇康寧杰瑞生物制薬有限公司 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ
JP7802667B2 (ja) * 2019-12-04 2026-01-20 江蘇康寧杰瑞生物制薬有限公司 腫瘍治療のための二重特異性融合タンパク質
EP4298128A4 (en) * 2021-02-23 2025-01-22 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Methods of preventing, alleviating or treating tumors
US20250011388A1 (en) * 2021-10-28 2025-01-09 Monash University Variant ctla4 proteins
WO2025085590A1 (en) * 2023-10-20 2025-04-24 Jecho Laboratories, Inc. Multifunctional pd1 fusion proteins
EP4574165A1 (en) 2023-12-21 2025-06-25 Egle Therapeutics Immunocytokine for cancer treatment
WO2025133175A1 (en) 2023-12-21 2025-06-26 Egle Therapeutics Immunocytokine for cancer treatment

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
CA2894506C (en) 2012-12-11 2021-08-10 Vib Vzw Anti-influenza antibody
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
DK3240801T3 (da) 2014-12-31 2021-02-08 Checkmate Pharmaceuticals Inc Kombinationstumorimmunterapi
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
US20180346571A1 (en) 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
FI3389699T3 (fi) 2015-12-15 2024-05-28 Oncoc4 Inc Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
KR20180096789A (ko) * 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
US11001631B2 (en) 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018026642A1 (en) 2016-08-03 2018-02-08 The Feinstein Institute For Medical Research C1q and hmgb1 fusion proteins and uses thereof
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN111051350B (zh) 2017-09-07 2022-11-01 苏州丁孚靶点生物技术有限公司 包含信号调节蛋白α的免疫缀合物
CN111433224B (zh) 2017-11-17 2024-03-19 南京传奇生物科技有限公司 抗pd-l1的单结构域抗体及其变体
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
CN115991787A (zh) 2018-06-05 2023-04-21 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
JP7712925B2 (ja) * 2019-12-04 2025-07-24 江蘇康寧杰瑞生物制薬有限公司 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ
JP7802667B2 (ja) * 2019-12-04 2026-01-20 江蘇康寧杰瑞生物制薬有限公司 腫瘍治療のための二重特異性融合タンパク質

Also Published As

Publication number Publication date
JP7359785B2 (ja) 2023-10-11
CN112399973B (zh) 2022-12-16
EP3802613A4 (en) 2022-03-09
JP2021526377A (ja) 2021-10-07
WO2019233413A1 (en) 2019-12-12
TW202003588A (zh) 2020-01-16
US12281163B2 (en) 2025-04-22
US20210095031A1 (en) 2021-04-01
US11634492B2 (en) 2023-04-25
US20210246210A1 (en) 2021-08-12
CN112399973A (zh) 2021-02-23
EP3802613A1 (en) 2021-04-14
TWI831789B (zh) 2024-02-11

Similar Documents

Publication Publication Date Title
CN112399973B (zh) 二聚体及其用途
JP7504952B2 (ja) イヌ化抗体
JP7847630B2 (ja) Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質
CN112351997B (zh) 与cd19结合的重链抗体
CN108290951B (zh) 优化抗cd3双特异性抗体和其用途
CN110945026B (zh) 仅有重链的抗bcma抗体
CN110041429B (zh) 抗cd-3抗体，与cd3及cd20结合的双特异性抗原结合分子，及其用途
WO2019096121A1 (en) Single-domain antibodies and variants thereof against pd-l1
US20250051413A1 (en) Chimeric molecules comprising il-12 agonist polypeptide
CN115894703A (zh) 具有经修饰重链恒定区的多特异性重链抗体
JP2023549851A (ja) 葉酸受容体アルファに結合する重鎖抗体
JP7712925B2 (ja) 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ
WO2022171080A1 (zh) 抗cd112r抗体及其用途
KR20260032536A (ko) EpCAM에 대한 다중특이 항원 결합 단백질
CN114174337A (zh) 针对犬ctla-4的犬源化抗体
CN116096416B (zh) 抗cldn-18.2抗体及其用途
CN114746448A (zh) 用于肿瘤治疗的双特异性融合蛋白
HK40037173A (en) Dimer and use thereof
HK40037173B (en) Dimer and use thereof
CN117510641A (zh) 靶向cd112r和tigit的双特异性抗体及其用途
KR20260013511A (ko) 암 치료를 위한 조합 요법
HK40077509A (en) Bispecific fusion protein for tumor treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination